Chronic hypnotic use at 10 years—does the brand matter?

Schonmann, Yochai; Goren, Or; Bareket, Ronen; Comaneshter, Doron; Cohen, Arnon D; Vinker, Shlomo

doi:10.1007/s00228-018-2531-4

Cited by 33 publications

(31 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Misuse, abuse or dependence on zolpidem is a worldwide problem [25][26][27]. In France, regulatory changes such as the addition of prescription constraints seem to have a higher impact on prescriptions than the information for physicians.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study

et al. 2020

View full text Add to dashboard Cite

Our objective was to quantify the impact on the use of zolpidem of the obligation implemented in France in 2017 to use secure prescription pads to prescribe it. We conducted a cohort study within the French SNDS healthcare database. Patients aged over 18 years of age were considered for inclusion. The number of prevalent users and incident episodes of zolpidem use were compared before the change in law (

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In another study where PCPs reported patient data, we found a lower rate of phytopharmaceutical and high rate of BZD use in Swiss primary care chronic insomnia patients (Maire et al., 2020). One hypothesis might be that PCPs initially prescribed phytopharmaceuticals and then, because patients do not respond to this treatment, felt entitled to switch patients to the more effective hypnotics, even though that meant potential long‐term treatment and addiction (Schonmann et al., 2018).…”

Section: Discussionmentioning

confidence: 99%

Treating insomnia in Swiss primary care practices: A survey study based on case vignettes

Linder

Duss

Dvořák

et al. 2020

Journal of Sleep Research

View full text Add to dashboard Cite

Guidelines recommend cognitive behavioural therapy for insomnia (CBT‐I) as first‐line treatment for chronic insomnia, but it is not clear how many primary care physicians (PCPs) in Switzerland prescribe this treatment. We created a survey that asked PCPs how they would treat chronic insomnia and how much they knew about CBT‐I. The survey included two case vignettes that described patients with chronic insomnia, one with and one without comorbid depression. PCPs also answered general questions about treating chronic insomnia and about CBT‐I and CBT‐I providers. Of the 820 Swiss PCPs we invited, 395 (48%) completed the survey (mean age 54 years; 70% male); 87% of PCPs prescribed sleep hygiene and 65% phytopharmaceuticals for the patient who had only chronic insomnia; 95% prescribed antidepressants for the patient who had comorbid depression. In each case, 20% of PCPs prescribed benzodiazepines or benzodiazepine receptor agonists, 8% prescribed CBT‐I, 68% said they knew little about CBT‐I, and 78% did not know a CBT‐I provider. In the clinical case vignettes, most PCPs treated chronic insomnia with phytopharmaceuticals and sleep hygiene despite their lack of efficacy, but PCPs rarely prescribed CBT‐I, felt they knew little about it, and usually knew no CBT‐I providers. PCPs need more information about the benefits of CBT‐I and local CBT‐I providers and dedicated initiatives to implement CBT‐I in order to reduce the number of patients who are prescribed ineffective or potentially harmful medications.

show abstract

“…This was consistent with an increased prevalence of Z-drugs, which steadily rose, e.g., in the United States from 0.05% in 1999−2000 to 0.47% in 2013−2014, by reflecting absolute and relative increases of ＋0.42% and ＋840% [8]. Moreover, even if guidelines recommend a short-term use (no more than 4 weeks), Z-drugs have been demonstrated to be associated with an increased risk of chronic use [2,[9][10][11].…”

Section: Introduction Backgroundmentioning

confidence: 99%

‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse

Orsolini

Chiappini

Grandinetti³

et al. 2021

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Although believed safer compared to short-acting benzodiazepines (BZD), in the past few years a growing concern has developed relating to the abuse of Z-drugs, and specifically of zolpidem. Here we aim to review the evidence for the misuse of zolpidem and describe several related cases collected in Italy. A comprehensive overview is here carried by using several databases, and by combining the search strategy of free text terms and exploding a range of MESH headings relating to the topics of Zolpidem and Abuse and/or Misuse as follows:

show abstract

Chronic hypnotic use at 10 years—does the brand matter?

Abstract: One in five new users of sedative-hypnotics will become a long-term user, but only 0.5% will become excessive users. Z-drugs were associated with an increased risk of chronic use.

Cited by 33 publications

References 51 publications

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study

Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study

Treating insomnia in Swiss primary care practices: A survey study based on case vignettes

‘Z-trip’? A Comprehensive Overview and a Case-series of Zolpidem Misuse

Contact Info

Product

Resources

About